ArticleHepatology international2026
A real-world multicenter study of statins in compensated advanced chronic liver disease on hepatic decompensation and mortality outcomes.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsStatins exert pleiotropic effects, including antiinflammatory, endothelial, and antifibrotic actions, which may slow the progression of cirrhosis. However, their use in patients with compensated advanced chronic liver disease (cACLD) remains limited due to concerns regarding potential hepatotoxicity, and data specific to this population remains sparse.
methodsWe conducted a retrospective, multinational cohort study of adult cACLD (LSM >10 kPa) patients using data from the Cirrhosis Outcome and Research Endeavor (CORE) consortium, across 13 centers in 8 countries. Baseline statin use was the exposure of interest. Associations with first and second hepatic decompensation, composite liver-related events, and all-cause and cause-specific mortality were assessed using Fine-Gray competing-risks regression across two sequentially adjusted multivariable models and an inverse probability of treatment weighting (IPTW) analysis.
resultsAmong 2267 patients, 786 (34.7%) were statin users. Statin use was independently associated with a lower risk of first decompensation (Model 1: sHR 0.64; Model 2: sHR 0.66; IPTW: sHR 0.56) and composite liver-related events (Model 1: sHR 0.61; Model 2: sHR 0.63; IPTW: sHR 0.50), with benefit most pronounced in the moderate-risk portal hypertension strata and MASLD subgroup. No association was observed with all-cause, liver-related, or cardiovascular mortality. Associations with second decompensation were inconsistent.
conclusionIn this large multinational cohort of cACLD patients, statin use was associated with reduced risk of hepatic decompensation and liver-related events, but not all-cause mortality. These findings support a potential benefit for statins in this population.
Indexed as
Identifiers
42873450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.